12:54 AM | 
Posted by
Dr.Proxy
30 May 2011
Final clinical trials are currently underway in the United States and Europe testing sugammadex, a member of a new class of reversal drugs, which may dramatically alter the practice of anesthesiology. Su refers to sugar and gammadex refers to the structural molecule, a modified cyclodextrin.
Mechanism of Action
The three-dimensional structure of sugammadex resembles a doughnut with a hydrophobic cavity and a hydrophilic exterior. Hydrophobic interactions trap the drug into the cyclodextrin cavity (the doughnut hole) forming a very tight complex at a 1:1 ratio with steroidal neuromuscular blocking drugs (rocuronium > vecuronium >> pancuronium) causing a rapid and long-acting reversal of neuromuscular blockade.
Subscribe to:
Posts (Atom)